DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer|HER2-negative Circulating Tumor Cells|Postmenopausal Female Patients
Interventions: DRUG: Ribociclib|DRUG: Eribulin
Sponsor: Prof. W. Janni